Western Blot: ULK2 Antibody [NBP1-88881] - Analysis in control (vector only transfected HEK293T lysate) and ULK2 over-expression lysate (Co-expressed with a C-terminal myc-DDK tag (3.1 kDa) in mammalian HEK293T cells).
Immunohistochemistry-Paraffin: ULK2 Antibody [NBP1-88881] - Staining of human urinary bladder shows cytoplasmic and membranous positivity in urothelial cells.
Western Blot: ULK2 Antibody [NBP1-88881] - Analysis in human cell line SH-SY5Y.
This antibody was developed against Recombinant Protein corresponding to amino acids: VVRRSNTSPMGFLRPGSCSPVPADTAQTVGRRLSTGSSRPYSPSPLVGTIPEQFSQCCCGHPQGHDSRSRNSSGSPVPQAQSPQSLLSGARLQSAPTLTDIYQNKQKLRKQHSDPVCPSHTGAGYSYSPQPSRPGSLGTSPTKH
Specificity of human ULK2 antibody verified on a Protein Array containing target protein plus 383 other non-specific proteins.
Mouse (92%), Rat (93%). Backed by our 100% Guarantee.
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
The concentration calculator allows you to quickly calculate the volume, mass or concentration of your vial. Simply enter your mass, volume, or concentration values for your reagent and the calculator will determine the rest.
Review this Product
Be the first to review our ULK2 Antibody and receive a gift card or discount.
PRODUCT AVAILABILITY: Update Regarding the Evolving COVID-19 Situation
Bio-Techne appreciates the critical role that you and our products and services play in research efforts to further scientific innovation and discovery. We are continually assessing our manufacturing and supplier capabilities during the COVID-19 situation and are implementing precautionary measures to ensure uninterrupted supply of products and services. Currently, and as we abide by local shelter in place orders across the world, we are fully operational and do not anticipate any material supply disruptions across our Bio-Techne brands and product lines. As the situation evolves, our goal is to utilize preventive measures to reduce the threat that COVID-19 poses to our ability to meet the needs of our customers globally.